Recursion announced a planned leadership transition: long‑time CEO Chris Gibson will become board chair and Najat Khan, PhD, the company’s chief R&D and commercial officer, will assume CEO responsibilities January 1. The move follows Recursion’s combination with Exscientia, strategic portfolio trims, and a pivot toward later‑stage clinical programs. Khan signalled a shift from platform‑building to delivering clinical proof‑points, emphasizing timelines and translational rigor. Investors and industry observers will watch management execution as Recursion aims to convert AI‑driven discovery into demonstrable clinical advancement.